Affiliation: Oregon Health and Science University
- Huntington's disease: a decade beyond gene discoveryPenelope Hogarth
Oregon Health and Science University, Campus Mail OP 32, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
Curr Neurol Neurosci Rep 3:279-84. 2003..The resultant advances in our understanding of the pathogenesis of the disorder are moving us toward rational therapies to slow the progression and delay the onset of the illness...
- Interrater agreement in the assessment of motor manifestations of Huntington's diseasePenelope Hogarth
Oregon Health and Science University, Portland, Oregon 97239 3098, USA
Mov Disord 20:293-7. 2005..We expect these findings to translate to a similar level of interobserver agreement in the clinical trial setting involving experienced investigators examining live patients...
- Sodium phenylbutyrate in Huntington's disease: a dose-finding studyPenelope Hogarth
Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
Mov Disord 22:1962-4. 2007..We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose-response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well-tolerated in human HD...
- Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson diseaseValerie C Anderson
Department of Neurological Surgery, Oregon Health and Science University, Portland, OR 97201, USA
Arch Neurol 62:554-60. 2005..Although it has been suggested that stimulation of the STN may be superior to stimulation of the GPi, comparative trials are limited...
- Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome)Robert A Egan
Casey Eye Institute, Department of Ophthalmology, Oregon Health and Science University, Portland 97201, USA
Am J Ophthalmol 140:267-74. 2005..Since the neuro-ophthalmologic and electroretinographic (ERG) features have never been well delineated, we describe them in 16 patients with PKAN...
- OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's diseaseMatthew A Brodsky
Department of Neurology, Oregon Health and Science University, and Parkinson's Disease Research, Education and Clinical Care Center, Portland VA Medical Center, Portland, Oregon, USA
Mov Disord 21:1487-90. 2006..When the stimulators were turned back on, the dyskinesias soon resolved. This article is a first report of a unique pattern of rebound-type dyskinesia that occurred in the off medication state produced by stopping STN DBS...
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and ParkinsonismJohn G Nutt
Department of Neurology, Oregon Health and Science University, Portland, Oregon 97201, USA
Mov Disord 23:1860-6. 2008..However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects...
- Multisite randomized trial of deep brain stimulationKenneth Follett
Arch Neurol 62:1643-4; author reply 1644-5. 2005
- Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onsetNancy S Wexler
Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
Proc Natl Acad Sci U S A 101:3498-503. 2004..37), shared environment (0.22), and nonshared environment (0.41) variances, confirming that approximately 40% of the variance remaining in onset age is attributable to genes other than the HD gene and 60% is environmental...